0000000000642943

AUTHOR

Franck Bonnetain

showing 23 related works from this author

Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

2014

SummaryBackground A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). Aim To estimate the maximum-tolerated dose (MTD) and to assess safety, efficacy, pharmacokinetics and quality of life. Methods Patients received a single TACE session with injection of 2 mL drug-eluting beads (DEBs; DC Bead 300–500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose-limiting toxicity (DLT) in 20% of patients. Results Twenty-one patients were enrolled, inclu…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyPharmacokinetic analysisSurgeryPharmacokineticsInternal medicineHepatocellular carcinomaToxicitymedicineIdarubicinPharmacology (medical)Myocardial infarctionbusinessAdverse effectObjective responsemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

2016

Background Frailty is highly prevalent in elderly people. While significant progress has been made to understand its pathogenesis process, few validated questionnaire exist to assess the multidimensional concept of frailty and to detect people frail or at risk to become frail. The objectives of this study were to construct and validate a new frailty-screening instrument named Frailty Groupe Iso-Ressource Evaluation (FRAGIRE) that accurately predicts the risk for frailty in older adults. Methods A prospective multicenter recruitment of the elderly patients was undertaken in France. The subjects were classified into financially-helped group (FH, with financial assistance) and non-financially …

Older personGerontologyRehabilitationFrailtybusiness.industryGeriatrics gerontologymedicine.medical_treatmentPublished ErratumMEDLINEEvaluation toolLoss of autonomy03 medical and health sciencesElderly0302 clinical medicinemedicine030212 general & internal medicineGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryResearch ArticleBMC Geriatrics
researchProduct

Pertinence et méthodes pour la conduite d'un essai de supériorité médico-économique en cancérologie

2009

L’existence de ressources economiques limitees et le souci d’allouer, au mieux, a la collectivite, les budgets disponibles, incitent a mener des essais dont le critere de jugement principal pourrait etre un critere medico-economique. Dans le champ de la cancerologie, l’institution de pauses therapeutiques et/ou la diminution de la frequence d’administration des chimiotherapies induit au prealable de s’assurer de la non-inferiorite de l’efficacite de tels schemas. Un autre objectif sous-jacent pourrait etre la demonstration de leur superiorite medico-economique. Dans ce contexte, les essais medico-economiques dont le critere de jugement principal est un critere composite, base sur le cout et…

Cancer ResearchAnalyse cout efficaciteOncologyPolitical scienceRadiology Nuclear Medicine and imagingHematologyGeneral MedicineHealth economyHumanitiesBulletin du Cancer
researchProduct

Critères de substitution: méthodes de validation et état des lieux en cancérologie digestive

2009

In oncology, overall survival is often referred to as the gold standard for the evaluation of a novel therapy in phase III clinical trials. The use of an earlier endpoint (intermediate endpoint) would allow to reduce the duration, the number of patients and/or the cost of the studies. Before being used as primary endpoint, it has to be validated as surrogate for overall survival. Two main statistical methods have been developed. The first evaluates the proportion of treatment effect on overall survival that can be attributable to the effect on the surrogate endpoint. The second, the meta-analytic approach, estimates the correlation between the treatment effect on the surrogate and its effec…

OncologyCancer Researchmedicine.medical_specialtySurrogate endpointbusiness.industryColorectal cancermedicine.medical_treatmentCancerPhases of clinical researchHematologyGeneral MedicineGold standard (test)Intermediate endpointmedicine.diseaseOncologyInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imagingbusinessAdjuvantBulletin du Cancer
researchProduct

Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival.

2007

Abstract Background Few population-based studies have reported jointly analyses of relative survival according to the following prognostic factors: tumour–node–metastasis (TNM) stage, age, number of examined and positive nodes, hormonal status, histological Scarff, Bloom and Richardson (SBR) grade, tumour extension, hormone receptor status and tumour multifocal status. Patients and methods Data on female invasive breast cancer were provided by the Cote d’Or breast cancer registry. The Kaplan–Meier method and log-rank test were used to estimate and compare the survival probability at 1, 5, 10 and 15 years. The effect of prognostic factors on survival was assessed with crude and relative mult…

OncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsRisk AssessmentDisease-Free SurvivalBreast cancerAge DistributionInternal medicineCause of DeathEpidemiologymedicineHumansStage (cooking)educationAgedNeoplasm StagingProbabilityProportional Hazards ModelsGynecologyAged 80 and overeducation.field_of_studyRelative survivalbusiness.industryCarcinoma Ductal BreastCancerHematologyProgesterone Receptor StatusMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival AnalysisLog-rank testCross-Sectional StudiesOncologyMultivariate AnalysisFemaleFrancebusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer

2011

Abstract Purpose. This prospective multicenter study explored different definitions of time to deterioration (TTD) in quality of life (QoL) scores, according to different cutoffs of the minimal clinically important difference (MCID) as a modality for longitudinal QoL assessment in breast cancer patients. Methods. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and BR-23 before surgery, after surgery, and 6 and 12 months later. The global health score, arm symptoms score (BRAS), and breast symptoms score were analyzed. For a given baseline score, QoL was considered to have deteriorated if this score decreased by ≥5 point…

Cancer Researchmedicine.medical_specialtyMultivariate analysisSentinel lymph node[SDV.CAN]Life Sciences [q-bio]/CancerBreast Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/CancerCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeInternal medicinemedicineHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overbusiness.industryProportional hazards modelSentinel Lymph Node BiopsyMinimal clinically important differenceMiddle Agedmedicine.diseasehumanities3. Good healthSurgeryOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisQuality of LifeLymph Node ExcisionFemalebusinessCohort study
researchProduct

Effect of dietary polyunsaturated fatty acids on the expression of peroxisomal ABC transporters

2008

Abstract Peroxisomal ABC transporters encoded by the ABCD genes are thought to participate in the import of specific fatty acids in the peroxisomal matrix. ABCD1 deficiency is associated with X-linked adrenoleukodystrophy (X-ALD), the most frequent peroxisomal disorder which is characterized by the accumulation of saturated very-long-chain fatty acids (VLCFA). ABCD2 (the closest homolog of ABCD1) and ABCD3 have been shown to have partial functional redundancy with ABCD1; only when overexpressed, they can compensate for VLCFA accumulation. Other lipids, for instance polyunsaturated fatty acids (PUFA), should be possible candidate substrates for the ABCD2 and ABCD3 gene products, ALDRP and PM…

MaleATP-binding cassette transporterBiologyBiochemistryDietary Fats UnsaturatedAdrenal GlandsPeroxisomal disorderPeroxisomesmedicineAnimalsPPAR alphachemistry.chemical_classificationReverse Transcriptase Polymerase Chain ReactionPeroxisomal matrixBrainGeneral MedicinePeroxisomemedicine.diseaseRatsGene Expression RegulationLiverBiochemistrychemistryDocosahexaenoic acidFatty Acids UnsaturatedACOX1ATP-Binding Cassette TransportersAdrenoleukodystrophyOxidation-ReductionPolyunsaturated fatty acidBiochimie
researchProduct

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

2010

Abstract Background The aim of this population-based study was to assess independent prognostic factors in ovarian cancer using relative survival (RS) and to investigate changes in RS rates from 1982 to 2005. Methods Data on 748 patients with ovarian cancer were provided by the Côte d'Or gynaecologic cancer registry. The RS was estimated using a generalized linear model with a Poisson error structure. Relative survival and its 95% confidence interval (CI) were described at the following specific time points 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with multivariate analyses of RS. Results The median follow-up was 12 years. The RS rates at 1, 3 and 5 years …

AdultOncologymedicine.medical_specialtyCancer ResearchMultivariate analysisAdolescentPopulationMedical Oncologylcsh:RC254-282Internal medicinemedicineGeneticsHumansRegistriesChildeducationSurvival rateAgedAged 80 and overOvarian NeoplasmsGynecologyeducation.field_of_studyRelative survivalbusiness.industryCancerMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseConfidence intervalSurvival RateSerous fluidTreatment OutcomeOncologyFemaleFranceOvarian cancerbusinessResearch ArticleBMC Cancer
researchProduct

Factors Associated With Fatigue After Surgery in Women With Early-Stage Invasive Breast Cancer

2013

Abstract Learning Objectives Describe the effect of worsening fatigue after breast cancer surgery on physical functioning and psychological distress. Better identify women at risk for developing cancer-related fatigue. Direct target interventions to patients most in need. Purpose. Fatigue is one of the most frequent symptoms in patients with cancer. However, the precise determinants of fatigue are still unknown. This study was conducted to investigate factors correlated with cancer-related fatigue before surgery and just before subsequent adjuvant therapy. Methods. Patients completed the Multidimensional Fatigue Inventory (MFI-20), the European Organization for Research and Treatment of Can…

MESH: FatigueCancer ResearchMultivariate analysisMESH: Lymph NodesDisease0302 clinical medicineMESH: Aged 80 and overQuality of lifeSurveys and Questionnaires030212 general & internal medicineNeoplasm Metastasisskin and connective tissue diseasesFatigueAged 80 and overMESH: AgedMESH: Middle AgedMESH: Neoplasm StagingMiddle Aged3. Good healthOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisAnxietyMarital statusFemalemedicine.symptomAdultmedicine.medical_specialtyBreast Neoplasms03 medical and health sciencesBreast cancerAdjuvant therapymedicineHumansNeoplasm InvasivenessMESH: Surveys and QuestionnairesAgedNeoplasm StagingMESH: Humansbusiness.industryCancerMESH: Quality of LifeMESH: AdultMESH: Neoplasm Invasivenessmedicine.diseaseMESH: Neoplasm MetastasisSurgeryQuality of Life[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieLymph NodesbusinessMESH: FemaleMESH: Breast Neoplasms
researchProduct

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.

2014

Our specialized population-based registry has allowed us to explore changes in incidence and survival by subtype over the last 30 years. Between 1980 and 2009, 4790 cases of lymphoid malignancies were registered using the International Classification of Diseases for Oncology. The incidence rate of lymphoid malignancies was 20.5 per 100,000 inhabitants per year, and ranged from 0.1 to 4 according to subtype. Five-year net survival was 65%, and ranged from 41% to 93% according to subtype. We observed an increase in 5-year net survival between the periods 1980-1989 and 2000-2009 (58% vs. 70%). This was observed in most but not all subtypes. Our long-standing population-based registry allowed u…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentLymphomaPopulationYoung AdultSurvival probabilityInternal medicinemedicineHumansRegistrieseducationChildNet SurvivalAgedAged 80 and overeducation.field_of_studyLeukemiabusiness.industryIncidence (epidemiology)IncidenceHematologyMiddle AgedSurvival AnalysisCancer registryOncologyLymphoid malignancyChild PreschoolHematologic NeoplasmsPopulation SurveillanceImmunologyFemaleFrancebusinessPopulation-Based RegistryInternational Classification of Diseases for OncologyFollow-Up StudiesLeukemialymphoma
researchProduct

Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Stud…

2016

Medical progress and the lifestyle modification have prolonged life expectancy, despite the development of chronic diseases. Support and care for older subjects are often provided by a network of informal caregivers composed of family, friends and neighbors, who are essential in helping older persons to continue living at home. It has been shown that the extent and diversity of informal tasks may jeopardize the physical, mental and social wellbeing of caregivers. The aim of the Informal Carers of Elderly cohort is to define, through a longitudinal study, profiles of caregivers of older patients with a diagnosis of one of the following diseases: cancer (breast, prostate, colorectal), neurode…

GerontologyMaleLongitudinal studyAgingComparative Effectiveness ResearchdemographyTime Factors[SDV]Life Sciences [q-bio]Health StatusHealth-related quality of lifeSocial WorkersMedicine (miscellaneous)DiseaseAnxietylaw.invention[SHS]Humanities and Social SciencesStudy Protocol0302 clinical medicineElderlyRandomized controlled trialCost of IllnesslawNeoplasmsHealth careAdaptation PsychologicalMedicinePharmacology (medical)030212 general & internal medicineLongitudinal StudiesProspective StudiesComputingMilieux_MISCELLANEOUSQualitative ResearchCancerCost-utility[SHS.DEMO] Humanities and Social Sciences/DemographyDepressionAge FactorsNeurodegenerative DiseasesMiddle Aged3. Good healthInformal caregiversCaregiversLongitudinal cohort studyCardiovascular DiseasesResearch DesignCohortFemaleFranceIndependent Living[SHS.DEMO]Humanities and Social Sciences/DemographyChronic disease03 medical and health sciencesSocial supportIntervention (counseling)HumansRandomized studyAgedbusiness.industrySocial SupportLife expectancyQuality of Lifebusiness[ SHS.DEMO ] Humanities and Social Sciences/Demography030217 neurology & neurosurgeryTrials
researchProduct

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

2011

Abstract Background There is no consensus about the most effective method for transarterial chemoembolisation of hepatocellular carcinoma. Aim The aim of this phase II trial was to compare the efficacy and toxicity of lipiodol transarterial chemoembolisation with amiodarone in association with pirarubicin or doxorubicin versus lipiodol transarterial chemoembolisation with anthracycline alone in a control group. Methods Patients with unresectable hepatocellular carcinoma and Child-Pugh A/B7 were considered eligible for the trial. transarterial chemoembolisation was repeated every 6 weeks for a maximum of 4 sessions. Results Thirteen patients were randomised in the amiodarone group, and 14 we…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAnthracyclinePirarubicinAmiodaroneKaplan-Meier EstimateAmiodaroneGastroenterologyDisease-Free Survivallaw.inventionExcipientsEthiodized OilRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansChemoembolization TherapeuticAgedHepatologybusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseSurgeryClinical trialTreatment OutcomeDoxorubicinHepatocellular carcinomaLipiodolFemalebusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissec…

2009

Background: This prospective multicenter study assessed and compared the impact of different surgical procedures on quality of life (QoL) in breast cancer patients. Patients and methods: The EORTC QLQ-C30 and the EORTC QLQ-BR-23 questionnaires were used to assess global health status (GHS), arm (BRAS) and breast (BRBS) symptom scales, before surgery, just after surgery and 6 and 12 months later. The Kruskal–Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. Results: Before surgery, GHS (P = 0.7807) and BRAS (P = 0.7688) QoL scores…

medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancerQuality of lifemedicineHumansProspective Studiesbusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionHematologySentinel nodeMiddle Agedmedicine.diseasehumanitiesSurgeryOncologyLymphatic MetastasisQuality of LifeLymph Node ExcisionLymphadenectomyFemaleBreast diseaseLymph NodesbusinessCohort studyAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Impact of socio-economic and surveillance characteristics on survival in patients with primary invasive breast cancer. A French population-based stud…

2008

[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer
researchProduct

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic age…

2011

Abstract Purpose. A better identification of patients who are more likely to benefit from vascular endothelial growth factor–targeted therapy is warranted in metastatic renal cell carcinoma (mRCC). As adipose tissue releases angiogenic factors, we determined whether parameters such as visceral fat area (VFA) were associated with outcome in these patients. Experimental Design. In 113 patients with mRCC who received antiangiogenic agents (bevacizumab, sunitinib, or sorafenib) (n = 64) or cytokines (n = 49) as first-line treatment, we used computed tomography to measure VFA and subcutaneous fat area (SFA). We evaluated associations linking body mass index (BMI), SFA, and VFA to time to progres…

SorafenibOncologyMaleCancer Researchmedicine.medical_specialtygenetic structuresIntra-Abdominal FatBevacizumabPopulationAngiogenesis InhibitorsIntra-Abdominal FatCohort StudiesGenitourinary Cancer: Renal Bladder and TesticularRenal cell carcinomaInternal medicinemedicineHumansNeoplasm MetastasiseducationSurvival rateCarcinoma Renal CellAgedRetrospective Studieseducation.field_of_studyNeovascularization PathologicSunitinibbusiness.industrymedicine.diseasePrognosisKidney NeoplasmsSurvival RateEndocrinologyTreatment OutcomeOncologyDisease ProgressionFemalebusinessBody mass indexmedicine.drugThe oncologist
researchProduct

The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study.

2008

International audience; Survival data on female invasive breast cancer with 9-year follow-up from five French cancer registries were analysed by logistic regression for prognostic factors of cancer stage. The Kaplan-Meier method and log-rank test were used to estimate and compare the overall survival probability at 5 and 7 years, and at the endpoint. The Cox regression model was used for multivariate analysis. County of residence, age group, occupational status, mammographic surveillance, gynaecological prevention consultations and the diagnosis mammography, whether within a screening framework or not, were independent prognostic factors of survival. Moreover, for the same age group, and on…

OncologyCancer ResearchEpidemiologyMESH : AgedMESH : Breast NeoplasmsLogistic regressionsurvival analysis0302 clinical medicineMESH: Aged 80 and overMESH : Population SurveillanceMESH : Socioeconomic FactorsMedicineMESH : Female030212 general & internal medicineAged 80 and overMESH: AgedMESH: Middle Agedmedicine.diagnostic_testCarcinoma Ductal Breast[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: European Continental Ancestry GroupMESH: Follow-Up StudiesMiddle AgedMESH : AdultMESH : Survival Rate3. Good healthSurvival RateOncology030220 oncology & carcinogenesisPopulation SurveillanceFemalemass screeningAdultmedicine.medical_specialtyMESH: Socioeconomic FactorsMESH: Survival RatemammographyMESH: MammographyBreast NeoplasmsWhite PeopleMESH: Population SurveillanceMESH : European Continental Ancestry Group03 medical and health sciencesBreast cancerbreast neoplasmInternal medicineMammographyHumansMESH : MammographyMESH : Middle AgedMESH: Mass ScreeningMESH : Aged 80 and overSurvival rateMass screeningSurvival analysisAgedGynecologyMESH : Mass ScreeningMESH: Humansbusiness.industryProportional hazards modelMESH : HumansMESH : Carcinoma Ductal BreastCancerMESH: AdultMESH : Follow-Up Studiesmedicine.diseaseMESH: Carcinoma Ductal BreastSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiesocio-economic factors[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleMESH: Breast NeoplasmsFollow-Up Studies
researchProduct

Correlation between clinical prognostic factors and MR spectroscopy-based biomarkers determined at 3.0 T without endorectal coils for patients with l…

2009

International audience

[ INFO.INFO-IM ] Computer Science [cs]/Medical Imaging[INFO.INFO-IM]Computer Science [cs]/Medical Imaging[INFO.INFO-IM] Computer Science [cs]/Medical ImagingComputingMilieux_MISCELLANEOUS
researchProduct

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubici…

2016

Objectives The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD). Setting This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. Patients had to complete the EORTC QLQ-C30 HRQoL questionnaire at baseline and at days 15, 30 and 60 after TACE. Participants Patients aged ≥18 years with HCC unsuitable for curative treatments were evaluated for the study (N=21). Primary and secondary outcome measurements The …

MaleOncologyHealth-related Quality of LifePhases of clinical research[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of life1506FatigueAntibiotics AntineoplasticLiver NeoplasmsGeneral MedicineMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisHepatocellular carcinomaToxicityFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology030211 gastroenterology & hepatology1717medicine.drugmedicine.medical_specialtyCarcinoma HepatocellularMaximum Tolerated Dose1722Pain[SDV.CAN]Life Sciences [q-bio]/CancerPhase 1Disease-Free Survival03 medical and health sciencesInternal medicineCarcinomamedicineHumansIdarubicinChemoembolization TherapeuticAgedHealth-related Quality of ifeOncology clinical trialHealth related quality of lifebusiness.industryResearchlongitudinal analysis[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologyphase Imedicine.diseaseSurgeryTime to deteriorationMaximum tolerated doseQuality of LifeIdarubicinbusinessBMJ Open
researchProduct

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of …

2011

Purpose The purpose of this study was to develop accurate models and nomograms to predict local recurrence, distant metastases, and survival for patients with locally advanced rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery and to allow for a selection of patients who may benefit most from postoperative adjuvant chemotherapy and close follow-up. Patients and Methods All data (N = 2,795) from five major European clinical trials for rectal cancer were pooled and used to perform an extensive survival analysis and to develop multivariate nomograms based on Cox regression. Data from one trial was used as an external validation set. The variables used in the ana…

OncologyMaleCancer ResearchColorectal cancerMESH : AgedKaplan-Meier EstimateMESH : Randomized Controlled Trials as Topiclaw.invention[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRandomized controlled triallawMESH : FemaleStage (cooking)Neoplasm MetastasisMESH: Models TheoreticalMESH : Rectal NeoplasmsSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARandomized Controlled Trials as TopicMESH: Aged0303 health sciencesMESH: Middle AgedMESH : Neoplasm Recurrence LocalAge FactorsMiddle AgedMESH : Adult3. Good healthEuropeOncology030220 oncology & carcinogenesisMESH : Neoplasm MetastasisFemaleMESH: Neoplasm Recurrence LocalAdultmedicine.medical_specialtyMESH : Sex FactorsMESH : MaleMESH : Europe[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Kaplan-Meier Estimate03 medical and health sciencesRECTAL CANCERSex FactorsMESH: Sex FactorsInternal medicinemedicineHumansMESH : Middle AgedSurvival analysisMESH: Kaplan-Meier Estimate030304 developmental biologyAgedMESH: Age FactorsMESH: HumansProportional hazards modelbusiness.industryRectal NeoplasmsMESH : Models TheoreticalMESH : HumansMESH: Rectal NeoplasmsMESH: AdultNomogramModels Theoreticalmedicine.diseaseMESH: Neoplasm MetastasisMESH: MaleSurgeryClinical trialMESH: Randomized Controlled Trials as TopicMESH : Age FactorsMESH: EuropeNeoplasm Recurrence LocalbusinessMESH: FemaleChemoradiotherapy
researchProduct

EARLY CHOLINE LEVELS FROM 3-TESLA MR SPECTROSCOPY AFTER EXCLUSIVE RADIATION THERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER ARE PREDICT…

2011

International audience; Abstract: Purpose: To investigate the time course response of prostate metabolism to irradiation using magnetic resonance spectroscopy (MRS) at 3-month intervals and its impact on biochemical control. Methods and Materials: Between January 2008 and April 2010, 24 patients with localized prostate cancer were prospectively enrolled in the Evaluation of the Response to Irradiation with MR Spectroscopy (ERIS) trial. All the patients had been treated with intensity-modulated radiation therapy with or without long-term adjuvant hormonal therapy (LTHT) and underwent 3-T MRS and prostate-specific antigen (PSA) assays at baseline and every 3 months thereafter up to 12 months.…

MaleIn vivo magnetic resonance spectroscopyCancer ResearchTime Factorsmedicine.medical_treatmentCholine030218 nuclear medicine & medical imagingchemistry.chemical_compoundProstate cancer0302 clinical medicineProstateCholineProspective StudiesProspective cohort studyProstate cancerRadiation[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingProstateOrgan SizeMiddle AgedTumor Burdenmedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPredictive value of testsHormonal therapyResponse monitoringmedicine.medical_specialtyUrologyCitric Acid03 medical and health sciencesBody WaterPredictive Value of TestsMagnetic resonance spectroscopymedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingAgedbusiness.industryProstatic NeoplasmsAndrogen AntagonistsProstate-Specific Antigenmedicine.diseaseRadiation therapychemistryRadiotherapy Intensity-Modulated3 TeslabusinessNuclear medicine
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

2010

Abstract Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of …

OncologyCancer ResearchTime FactorsDigestive System Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of lifeSurveys and QuestionnairesMedicine030212 general & internal medicineMESH: Treatment OutcomeResponse rate (survey)MESH : Evidence-Based MedicineClinical Trials as TopicEvidence-Based MedicineMESH: Endpoint DeterminationMESH: Research DesignMESH : QuestionnairesMESH : Research Designlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMESH: Reproducibility of Resultsmedicine.anatomical_structureTreatment OutcomeOncologyResearch Design030220 oncology & carcinogenesisData Interpretation StatisticalMESH: Survival AnalysisMESH : Disease-Free SurvivalMESH : Endpoint DeterminationFranceMESH : Time FactorsResearch Articlemedicine.medical_specialtyMESH: Clinical Trials as TopicEndpoint DeterminationRectum[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Treatment Outcomelcsh:RC254-282Disease-Free Survival03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneticsHumansMESH : Data Interpretation StatisticalMESH : FranceSurvival analysisMESH: Humansbusiness.industrySurrogate endpointMESH: Digestive System NeoplasmsMESH : Reproducibility of ResultsMESH: QuestionnairesMESH : HumansMESH: Time FactorsCancerReproducibility of ResultsMESH: Quality of LifeMESH : Quality of Lifemedicine.diseaseSurvival AnalysisMESH : Clinical Trials as TopicMESH: FranceLocalized diseaseEndpoint DeterminationMESH: Disease-Free SurvivalQuality of LifeMESH : Digestive System NeoplasmsMESH : Survival AnalysisbusinessMESH: Data Interpretation StatisticalMESH: Evidence-Based MedicineBMC Cancer
researchProduct

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

2016

International audience; Background: Frailty is highly prevalent in elderly people. While significant progress has been made to understand its pathogenesis process, few validated questionnaire exist to assess the multidimensional concept of frailty and to detect people frail or at risk to become frail. The objectives of this study were to construct and validate a new frailty-screening instrument named Frailty Groupe Iso-Ressource Evaluation (FRAGIRE) that accurately predicts the risk for frailty in older adults.Methods: A prospective multicenter recruitment of the elderly patients was undertaken in France. The subjects were classified into financially-helped group (FH, with financial assista…

MaleGerontologyMultivariate statisticsmedicine.medical_treatmentlcsh:GeriatricsLogistic regression0302 clinical medicineElderlySurveys and QuestionnairesPrevalenceadultsProspective Studies030212 general & internal medicineelderly-peopleAged 80 and overeducation.field_of_studyRehabilitationFrailty[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyPrognosisEvaluation tool3. Good healthLoss of autonomyFemaleFranceErratummedicine.medical_specialtyPsychometricsFrail ElderlySeparation (statistics)Population[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyRisk AssessmentSensitivity and Specificity03 medical and health sciencesCronbach's alphamedicineHumanseducationGeriatric AssessmentAgedmodelbusiness.industryUnivariateReproducibility of ResultsConfidence intervallcsh:RC952-954.6Logistic ModelsPhysical therapyGeriatrics and Gerontologybusiness030217 neurology & neurosurgerydementia
researchProduct